| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.051 | 0.1 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.1 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.1 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.1 |
| mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.1 |
| mRNA | CAY10576 | CTRPv2 | pan-cancer | AAC | 0.058 | 0.1 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.055 | 0.1 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | -0.051 | 0.1 |